Submucosal bioresorbable drug eluting platform

A method for treating symptoms of a condition, the method comprising:

• inserting a distal tip of a needle submucosally into a target tissue;
• delivering a plurality of bioresorbable drug delivery platforms from the needle into the target tissue, each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms comprising an active agent of from about 40% to about 60% of the drug delivery platform by mass and contained within a polymer scaffold of from about 40% to about 60% of the drug delivery platform by mass, wherein a sum of the percentage by mass of the polymer scaffold and the percentage by mass of the active agent is equal to or less than 100%;
• allowing a dose of the active agent to be released from each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms over a sustained period of time, wherein the release from each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms over the sustained period of time provides a therapeutically effective amount of the active agent in the target tissue;
• and
• allowing each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms to biodegrade within the target tissue,
• wherein each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms is configured in size and mechanical integrity to pass through the needle for implantation submucosally into the target tissue, and such that the sustained period of time is from about 6 months to about 9 months,
• wherein each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms has a biased distribution of the active agent radially out from a center of each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms.